Seomagen Obtains Clinical Laboratory Certification from New York State Department of Health, Proving Global Genomics Analysis Competitiveness

Global genomics analysis specialist company, Seomagen, has strengthened its foothold in the U.S. clinical diagnostics market by obtaining clinical laboratory certification from the New York State Department of Health.

On June 25, Seomagen announced that it officially acquired a Clinical Laboratory Permit in the field of Molecular Genetic Testing from the New York State Department of Health on June 18.

This certification means that Seomagen has secured the official qualification to directly receive and analyze clinical test samples in New York State. Through this, the company has established a foundation to offer genomics-based diagnostic services in New York, one of the major healthcare markets in the United States.

In order to operate a clinical laboratory in the U.S., Clinical Laboratory Improvement Amendments (CLIA) certification, overseen by the federal government, is generally required. However, New York State is the only region in the U.S. that requires its own separate clinical laboratory permit, effectively operating a dual certification system.

In particular, the New York State Department of Health's clinical laboratory certification is known for demanding the highest level of regulatory and quality standards in the U.S. Seomagen explained that, through this achievement, the quality of testing, analytical accuracy, and operational capabilities of its CLIA Lab have been officially recognized.

The company expects that this certification will serve as proof of its global-level quality competitiveness, not only granting the right to handle clinical samples in New York State. Based on this, Seomagen plans to further increase trust in the clinical diagnostics market and accelerate the expansion of its business within the United States.

Hong Soo, CEO of Seomagen, stated, "Obtaining this certification is significant not only because we can now receive clinical samples from New York State, but also because passing the state's rigorous standards proves the global-level quality and accuracy of Seomagen's CLIA Lab."

He added, "Through this clinical laboratory certification from New York State, we have secured the legal qualification to directly receive patient samples and provide diagnostic services in the New York region, one of the key medical markets in the U.S. We expect to increase sales and market share in the U.S. going forward and will continue to expand our clinical diagnostic service areas to provide top-tier genomics analysis services."

Seomagen plans to use this New York State certification as a stepping stone to strengthen its position in the U.S. clinical diagnostics market and further enhance its competitiveness as a global genomics analysis company.

This content was produced with the assistance of AI translation services.